%3Amax_bytes(150000)%3Astrip_icc()%2FTAL-header-east-african-rift-valley-ethiopia-NEWOCEAN0525-32318b66bc0f47b79fed7cc183d7e507.jpg&w=3840&q=100)
This Continent Is Splitting and Might Create a New Ocean on Earth
Due to tectonic plate movement, part of eastern Africa is slowly splitting apart, which could lead to the creation of a sixth ocean in one million to 20 million years. (While a million years is a long time by human life scale, it's considered to be a small time on a geological scale.)
What is currently the countries of Djibouti, Ethiopia, and Eritrea could be slowly moving away from the rest of the continent, eventually breaking off and allowing water from the Indian Ocean to rush in to fill the gap. This would lead to a separate land mass, new coastlines, and a change in climate patterns and geography for northeast Africa.
This area is part of the East African Rift System (EARS), home to an active continental rift zone, where one plate is slowly pulling away from another one. According to research on the plates, parts of the rift are separating at a rate of .3 inches per year due to the movement of magma deep below the surface. Scientists were alerted to its relatively rapid movement due to a large fissure that appeared in Ethiopia in 2005.
This isn't, of course, certain but scientific experts believe it's likely since similar geological activities created the Saudi Arabian peninsula.
'In the future, as extension continues along the rift, the rift valley will sink lower and lower eventually allowing ocean waters to flood into the basin. If rifting continues, new basaltic oceanic crust may form along the centre of the rift producing a new narrow ocean basin with its own mid ocean ridge between the Nubian and Somalian plates,' the London Geographical Society says on its website.
The movement of tectonic plates can be responsible for volcanoes, geysers, and valleys when the plates move apart, and large mountain ranges when they move together, as well as earthquakes. The last new ocean to be identified was the Southern Ocean around Antarctica in 2021.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Geological report taken out of context to claim that new ocean has emerged in East Africa
Last May, a US magazine reported on a geological change taking place in Africa that could be very slowly splitting the continent apart. A video post recently circulating on Facebook uses a screenshot from the report to claim that a new ocean has emerged in East Africa, uniting Ethiopia and Djibouti. However, this is misleading: The report explains that geological processes in northeast Africa, which could form a new ocean over millions of years, are gradually creating a separate tectonic plate for Ethiopia, Djibouti and Eritrea. It does not state that a new ocean has already formed, nor that Ethiopia and Djibouti are uniting. The post shared on Facebook on August 5, 2025, in Amharic claims: 'Ethiopia and Djibouti are uniting. Scientists have announced amazing findings.' 'The new ocean has been formed,' adds the post. The post contains 90 seconds of footage showing images of volcanoes and rifts in northeastern part of Africa. Photos of Ethiopian and Djiboutian leaders are also displayed. The video begins with a male narrator repeating the headline of the story. 'Ethiopia and Djibouti unite. Scientists have announced tantalising findings. The scientists say that the Red Sea is expanding to the East African countries, which has created a new ocean,' he adds. As the speaker talks, a screenshot of a report appears on the screen with the headline 'This Continent is Splitting and Might Create a New Ocean on Earth". He goes on to claim that scientists confirm that the earthquakes that have occurred in Ethiopia, Turkey and Egypt are creating a new ocean in Ethiopia. 'It is confirmed that Ethiopia and Djibouti are the birthplace of the new ocean,' he further claims, adding, 'The event will dramatically change the shape of the earth'." As he speaks, East African maps, volcanoes, earthquakes and bodies of water are again shown on the screen. In 2005, a dramatic fissure more than 35 km long suddenly opened in Ethiopia's Afar Depression. Scientists said this was a vivid example of rapid crustal deformation and provided real-time evidence of a rift taking place over millions of years (archived here). However, neither the report nor other studies confirmed the emergence of a new ocean. No new ocean Using keyword searches, AFP Fact Check identified the screenshot used in the video. It was taken from a Travel + Leisure magazine article published on May 14, 2025, and titled 'This Continent Is Splitting and Might Create a New Ocean on Earth.' The article explains that tectonic activity in northeastern Africa — particularly in Djibouti, Ethiopia and Eritrea — is very gradually causing the land to pull apart (archived here). The article clearly states that it would take millions of years for such an ocean to develop. It cites the London Geographical Society's website: 'In the future, as extension continues along the rift, the rift valley will sink lower and lower eventually allowing ocean waters to flood into the basin. If rifting continues, new basaltic oceanic crust may form along the centre of the rift producing a new narrow ocean basin with its own mid ocean ridge between the Nubian and Somalian plates.' The article does not claim that a new ocean already exists in East Africa, nor that Ethiopia and Djibouti are uniting as a result. No study supports these claims. What scientists have documented is an ongoing tectonic rifting process that is not yet complete and will continue over a vast timescale. Solve the daily Crossword
Forbes
6 days ago
- Forbes
Don't Miss Saturday's Sky Show As The Moon Joins The ‘Planet Parade'
The moon will this Saturday, Aug. 17, join a 'planet parade' building in the morning sky. As it does so, it will brush past the Pleiades, a sparkling open cluster of stars that's best known for dominating the winter night sky. Best seen about an hour before sunrise, bright planets Venus and Jupiter will continue to dominate in the east while Saturn brightens in the south. Rising below Venus and Jupiter will be Mercury, though Uranus and Neptune — despite also being in the sky — are not visible to the naked eye. A spectacular 'planet parade' (also called an alignment) featuring six planets is visible during August 2025. getty This "planet parade" is taking place in the morning sky, so you'll need to get up early to see it. The best time to look is between about two hours and an hour before sunrise, though if you observe until about 45 minutes before sunrise, you may see tiny Mercury join the parade. About an hour before sunrise on Saturday, Aug. 16, Venus and Jupiter will be very bright in the eastern sky. They will shine at magnitudes -3.9 and -1.8, respectively, and will appear to be about four degrees from each other. Saturn will shine in the southern sky at magnitude 0.8. Mercury will appear below 10 degrees altitude in the east, according to NASA, so observe from a location with an unobstructed eastern horizon. Note that the exact rise times of planets depend on your location. The moon, now half-lit as it reaches its last quarter phase, will shine in the east-southeast about three degrees from the Pleaides, also known as M45 and the 'Seven Sisters' stars. The next big highlight of the 'planet parade' will come on Wednesday, Aug. 20, when a slender crescent moon will shine very close to a brilliant Venus. The planets an hour before sunrise on Saturday, Aug. 16, 2025, during the "planet parade." Stellarium This planet parade follows one in the evening sky in February, when five planets were visible together. Strictly speaking, they do not exist because they are entirely due to Earth's point of view of the rest of the solar system as it orbits the sun. Although all the planets orbit the sun on the same plane, they do so at vastly different distances and, therefore, apparent speeds as seen from Earth. For example, Venus and Jupiter appear very close to each other, but while Jupiter is four times farther away than Venus. Planet Parades always occur just before sunrise or sunset because Mercury — which is very close to the sun, relatively speaking — is usually lost in the sun's glare. When it is visible, it's not far from it. Either way, nothing is ever 'aligned'—that's an error. The planet parade really gets going this weekend as the moon joins the fray. On Monday, Aug. 18, a 26% crescent moon will be seen near Venus and Jupiter. On Tuesday, Aug. 19, Mercury will be at its highest in the morning sky as a 16%-lit crescent moon forms a curve with Venus and Jupiter. On Wednesday, Aug. 20, a 9%-lit crescent moon will be close to Venus, with Mercury below and Jupiter above. On Thursday, Aug. 21, a 4%-lit waning crescent moon will be beneath Jupiter and Venus, close to Mercury. The following planet parade will occur in October 2028, when five planets will be visible together, again before sunrise. Further Reading Forbes A 'Planet Parade,' A 'Black Moon' And A Meteor Shower: The Night Sky In August 2025 By Jamie Carter Forbes Why Friday May See The Perseid Meteor Shower At Its Best By Jamie Carter Forbes When To See The Fabulous Sky Show On Tuesday As 'Shooting Stars' Fall By Jamie Carter
Business Wire
7 days ago
- Business Wire
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the three months ended June 30, 2025, as well as key recent clinical and corporate developments. 'Commercial and regulatory momentum for Multikine is accelerating due to three driving factors—our partnership negotiations in Saudi Arabia, the increasing interest in CEL-SCI from investors in the Middle East, and continued recognition in the global scientific and regulatory community that PD-L1 is a valuable predictive marker for head and neck cancer,' stated CEL-SCI CEO, Geert Kersten. 'We are particularly encouraged about the potential for Multikine to become commercially available in Saudi Arabia in 2025. Should this happen, we believe it could support our regulatory and commercial efforts worldwide.' Corporate and Clinical Developments include: CEL-SCI's CEO and a Director of the Company each purchased a combined total of 32,116 shares of restricted common CEL-SCI stock in July 2025. Gross proceeds of approximately $5.7 million were raised by CEL-SCI in July 2025 through the sale of 1,500,000 shares of common stock at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. In May of 2025, the Company raised gross proceeds of $5 million through the sale of 2,000,000 shares of common stock priced at $2.50 per share. CEL-SCI is set to sign a commercialization and regulatory partnership agreement with a leading Saudi Arabian pharmaceutical company for Multikine* (Leukocyte Interleukin, Injection) in the treatment of head and neck cancer in the Kingdom of Saudi Arabia. A Breakthrough Medicine Designation application for Multikine was filed by the pharma partner with the Saudi Food and Drug Authority (SFDA). According to the SFDA, the response time to a Breakthrough Medicine Designation application is approximately 60 days. Following the granting of the Breakthrough Medicine Designation, Multikine would immediately become available for patient access and reimbursement/sale in Saudi Arabia. Several leading Saudi funds have expressed interest in investing in CEL-SCI, Multikine and/or a potential joint venture to serve the wider Middle East and North Africa (MENA) market. CEL-SCI's offering with Multikine is in line with Saudi Arabia's Vision 2030 initiative which seeks to make the Kingdom a global biotech hub. Given the SFDA's 60-day timeline to make Multikine potentially available, in-country investors have expressed interest in bringing a much-needed cancer treatment to market while also supporting their nation's health-tech goals. A new study supports CEL-SCI's strategy to seek early approval in the U.S. CEL-SCI is in final preparations before starting enrollment of its 212-patient Confirmatory Registration Study for Multikine in newly diagnosed locally advanced head and neck cancer patients. The U.S. Food and Drug Administration (FDA) has given CEL-SCI the go-ahead for the study. CEL-SCI plans to seek early approval based on early tumor responses. A third-party study recently published in Cancer Cell titled 'Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies' provides support for CEL-SCI's approach. The concept that tumor responses predict survival has been acknowledged for many cancer types and has led to accelerated approval of many cancer drugs. The third-party study published in Cancer Cell gives further support that this is also true in the neoadjuvant pre-surgical immunotherapy treatment of head and neck cancer. More data on PD-L1 as a predictive biomarker signals a clear regulatory pathway for Multikine in PLD-L1 negative patients. There is a growing body of data on PD-L1 as a predictive biomarker and diagnostic for cancer. In June, the FDA approved Merck's KEYTRUDA® (pembrolizumab), an anti-PD-L1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1. Of note, the FDA granted Merck priority review in February 2025 and approval in June 2025 based on interim results. This sets a positive precedent for Multikine in PD-L1 low and negative patients. Multikine reduced the risk of death by 66% compared to standard of care in the target population of patients with low and zero PD-L1, while Keytruda reduced the risk of recurrence and progression (EFS) by only 30% compared with standard of care in patients whose tumors expressed higher PD-L1 without demonstrating improvement in overall survival. Financial Results During the three months ended June 30, 2025, net loss available to common shareholders was $5.7 million compared to $7.5 million in the prior year period. Basic and diluted net loss per common share was $1.36 for the three months ended June 30, 2025, compared to $4.18 for the three months ended June 30, 2024. In demonstration of his deep commitment to the Company and Multikine's potential to significantly improve patient outcomes, CEO Geert Kersten has been and is currently working without taking a salary. About CEL-SCI Corporation CEL-SCI believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor before surgery, radiation and chemotherapy because that is the time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. Based on the data from the completed randomized controlled Phase 3 study of 928 patients, the FDA concurred with CEL-SCI's target patient selection criteria and gave the go-ahead to conduct a confirmatory Registration Study which will enroll 212 patients. CEL-SCI will enroll newly diagnosed locally advanced not yet treated resectable head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy), representing about 100,000 patients annually. The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2024. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. * Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.
